- Supported exchanges /
- F /
- 722.F
ANTENGENE CORP. DL-0001 (722 F) stock market data APIs
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors. The company also develops other clinical stage assets, such as ATG-016, a second generation XPO1 inhibitor, which is in Phase II open-label study in patients with patients with high-risk myelodysplastic syndromes; ATG-017, an ERK1/2 inhibitor for the treatment of advanced/metastatic solid tumors and hematologic malignancies; ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma; ATG-037, an CD73 inhibitor for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; and ATG-031 an anti-CD24 monoclonal antibody. In addition, its pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor and ATG102, an LILRB4 x CD3 T cell engager. Further, it develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
ANTENGENE CORP. DL-0001 Financial Data Overview
| 0.0665 | |
| 0.0665 | |
| - | |
| 0.0665 | |
| 0.0665 | |
| 0.025-0.238 | |
| 68 764 K | |
| 611 M | |
| 56 068 K | |
| 0.863 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ANTENGENE CORP. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 56 068 K
- EBITDA -530 321 984
- Earnings Per Share -0.11
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ANTENGENE CORP. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ANTENGENE CORP. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
